West Pharmaceutical Servs Analyst Price Targets

Wall Street analyst price targets and consensus rating for West Pharmaceutical Servs (WST).

Price Target Range — 10 Quarters

Analyst Consensus — 13 Analysts

13Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$425Upside to Avg. PT+2.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$412→$494
Oct 30, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$420→$500
Oct 30, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$440→$500
Oct 30, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$440→$480
Oct 13, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$410→$420
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$400→$440
Sep 22, 2026	Morgan Stanley	Kallum Titchmarsh	Upgrade	Equal-Weight→Overweight	$365→$400
Sep 9, 2026	UBS	Doug Schenkel	PT Raise	Buy	$340→$415
Aug 3, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$400→$412
Jul 27, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$410→$425
Jul 13, 2026	BNP Paribas	Curtis Moiles	Initiate	Outperform	$447
Jul 9, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$325→$365
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$390→$410
Jul 2, 2026	Keybanc	Paul Knight	PT Raise	Overweight	$350→$390
Jun 9, 2026	Barclays	Luke Sergott	Upgrade	Equal-Weight→Overweight	$310→$400
Jun 2, 2026	Stephens & Co.	Steven Etoch	Maintained	Overweight	$360
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	—
May 29, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$315→$325
Apr 27, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$275→$310
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$265→$275

Analyst Ratings News

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494

Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $412 to $494.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500

TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $420 to $500.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $440 to $480.

Benzinga Newsdesk

This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History

Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.

Piero Cingari

PRO
CNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF

Benzinga Newsdesk

West Pharmaceutical Services Inc

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494

PRO
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480

This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History

PRO
CNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF

People Also Watch

People Also Watch

West Pharmaceutical Services Inc

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494

PROTD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500

PROBarclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500

PROEvercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480

This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History

PROCNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF

People Also Watch

People Also Watch

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494

PRO
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480

PRO
CNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF